Article
Maui, Hawaii - Preliminary results from an open-label study suggest PUVA-bexarotene is a safe and effective combination regimen for the treatment of early cutaneous T-cell lymphoma (CTCL), Joan Guitart, M.D., said at the annual Hawaii Dermatology Seminar, sponsored by the Skin Disease Education Foundation.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.